{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\nTET2 is an α‐ketoglutarate–dependent dioxygenase that catalyzes the iterative oxidation of 5‑methylcytosine in DNA to form 5‑hydroxymethylcytosine—and further oxidized derivatives—which contributes to active DNA demethylation and regulation of gene transcription. Structural studies have revealed that TET2 displays a compact catalytic core that precisely recognizes CpG dinucleotides, while its activity is modulated by cofactor binding and protein–protein interactions (for example, with the O‑GlcNAc transferase) and can even be affected by upstream metabolic alterations such as the accumulation of 2‑hydroxyglutarate. These features underscore how TET2 serves as an epigenetic “writer” that specifies DNA hydroxymethylation patterns and, by extension, chromatin configuration and gene expression."}, {"type": "fg", "children": [{"type": "fg_fs", "start_ref": "1", "end_ref": "5"}]}, {"type": "t", "text": "\n"}]}, {"type": "t", "text": "\n\n"}, {"type": "p", "children": [{"type": "t", "text": "\nIn the hematopoietic compartment, proper TET2 function is critical for normal stem cell self‑renewal and lineage commitment. Loss‑of‑function mutations in TET2 result in a marked reduction of global 5‑hydroxymethylcytosine levels, culminating in aberrant DNA hypermethylation and dysregulation of gene networks that govern myeloid differentiation. Such defects contribute to enhanced stem/progenitor cell self‑renewal, skewed differentiation (often favoring the monocytic lineage), and impaired hematopoietic maturation—all of which have been implicated in the pathogenesis of diverse myeloid and lymphoid malignancies. Moreover, studies have demonstrated that the order in which TET2 mutations arise relative to other oncogenic events (for example, JAK2 or IDH mutations) can influence disease evolution and clinical behavior."}, {"type": "fg", "children": [{"type": "fg_fs", "start_ref": "6", "end_ref": "13"}]}, {"type": "t", "text": "\n"}]}, {"type": "t", "text": "\n\n"}, {"type": "p", "children": [{"type": "t", "text": "\nBeyond its direct role in epigenetic reprogramming, TET2 contributes to the regulation of inflammatory responses in innate immune cells. In this context, TET2 can actively repress the transcription of inflammatory cytokines such as interleukin‑6 by recruiting histone deacetylases, thus ensuring proper resolution of inflammation. The influence of TET2 on chromatin and transcription also appears to affect clonal hematopoiesis during aging and may be linked to an increased risk of inflammatory and cardiovascular disorders. Such findings emphasize the dual roles of TET2—not only as a mediator of DNA methylation dynamics but also as an important regulator of immune homeostasis."}, {"type": "fg", "children": [{"type": "fg_fs", "start_ref": "14", "end_ref": "18"}]}, {"type": "t", "text": "\n"}]}, {"type": "t", "text": "\n\n"}, {"type": "p", "children": [{"type": "t", "text": "\nA multitude of studies have examined the clinical and biological impact of TET2 mutations across a spectrum of hematologic disorders. Recurring somatic mutations and deletions in TET2 have been documented in various myeloproliferative neoplasms, myelodysplastic syndromes, acute myeloid leukemia, and even select lymphoid malignancies, with mutation frequencies and allelic burdens displaying disease‐ and age‑related trends. Some reports have detailed how TET2 mutations may precede or follow other oncogenic hits and influence both prognosis and response to therapies—such as hypomethylating agents—in affected patients. Furthermore, clonal expansion of TET2‑mutant cells is now recognized as a feature of aging, linking epigenetic dysregulation to both malignant transformation and non‑malignant conditions."}, {"type": "fg", "children": [{"type": "fg_fs", "start_ref": "19", "end_ref": "32"}]}, {"type": "t", "text": "\n"}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Myunggon Ko, Yun Huang, Anna M Jankowska, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Nature (2010)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/nature09586"}], "href": "https://doi.org/10.1038/nature09586"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "21057493"}], "href": "https://pubmed.ncbi.nlm.nih.gov/21057493"}]}, {"type": "r", "ref": 2, "children": [{"type": "t", "text": "Wei Xu, Hui Yang, Ying Liu, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Cancer Cell (2011)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.ccr.2010.12.014"}], "href": "https://doi.org/10.1016/j.ccr.2010.12.014"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "21251613"}], "href": "https://pubmed.ncbi.nlm.nih.gov/21251613"}]}, {"type": "r", "ref": 3, "children": [{"type": "t", "text": "Qiang Chen, Yibin Chen, Chunjing Bian, et al. "}, {"type": "b", "children": [{"type": "t", "text": "TET2 promotes histone O-GlcNAcylation during gene transcription."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Nature (2013)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/nature11742"}], "href": "https://doi.org/10.1038/nature11742"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "23222540"}], "href": "https://pubmed.ncbi.nlm.nih.gov/23222540"}]}, {"type": "r", "ref": 4, "children": [{"type": "t", "text": "Myunggon Ko, Jungeun An, Hozefa S Bandukwala, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Nature (2013)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/nature12052"}], "href": "https://doi.org/10.1038/nature12052"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "23563267"}], "href": "https://pubmed.ncbi.nlm.nih.gov/23563267"}]}, {"type": "r", "ref": 5, "children": [{"type": "t", "text": "Di Wu, Di Hu, Hao Chen, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Glucose-regulated phosphorylation of TET2 by AMPK reveals a pathway linking diabetes to cancer."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Nature (2018)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/s41586-018-0350-5"}], "href": "https://doi.org/10.1038/s41586-018-0350-5"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "30022161"}], "href": "https://pubmed.ncbi.nlm.nih.gov/30022161"}]}, {"type": "r", "ref": 6, "children": [{"type": "t", "text": "Omar Abdel-Wahab, Ann Mullally, Cyrus Hedvat, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Blood (2009)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1182/blood-2009-03-210039"}], "href": "https://doi.org/10.1182/blood-2009-03-210039"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "19420352"}], "href": "https://pubmed.ncbi.nlm.nih.gov/19420352"}]}, {"type": "r", "ref": 7, "children": [{"type": "t", "text": "Saskia M C Langemeijer, Roland P Kuiper, Marieke Berends, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Acquired mutations in TET2 are common in myelodysplastic syndromes."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Nat Genet (2009)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/ng.391"}], "href": "https://doi.org/10.1038/ng.391"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "19483684"}], "href": "https://pubmed.ncbi.nlm.nih.gov/19483684"}]}, {"type": "r", "ref": 8, "children": [{"type": "t", "text": "Maria E Figueroa, Omar Abdel-Wahab, Chao Lu, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Cancer Cell (2010)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.ccr.2010.11.015"}], "href": "https://doi.org/10.1016/j.ccr.2010.11.015"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "21130701"}], "href": "https://pubmed.ncbi.nlm.nih.gov/21130701"}]}, {"type": "r", "ref": 9, "children": [{"type": "t", "text": "Kelly Moran-Crusio, Linsey Reavie, Alan Shih, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Cancer Cell (2011)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.ccr.2011.06.001"}], "href": "https://doi.org/10.1016/j.ccr.2011.06.001"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "21723200"}], "href": "https://pubmed.ncbi.nlm.nih.gov/21723200"}]}, {"type": "r", "ref": 10, "children": [{"type": "t", "text": "Cyril Quivoron, Lucile Couronné, Véronique Della Valle, et al. "}, {"type": "b", "children": [{"type": "t", "text": "TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Cancer Cell (2011)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.ccr.2011.06.003"}], "href": "https://doi.org/10.1016/j.ccr.2011.06.003"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "21723201"}], "href": "https://pubmed.ncbi.nlm.nih.gov/21723201"}]}, {"type": "r", "ref": 11, "children": [{"type": "t", "text": "François Lemonnier, Lucile Couronné, Marie Parrens, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Blood (2012)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1182/blood-2012-02-408542"}], "href": "https://doi.org/10.1182/blood-2012-02-408542"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "22760778"}], "href": "https://pubmed.ncbi.nlm.nih.gov/22760778"}]}, {"type": "r", "ref": 12, "children": [{"type": "t", "text": "Rafael Bejar, Allegra Lord, Kristen Stevenson, et al. "}, {"type": "b", "children": [{"type": "t", "text": "TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Blood (2014)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1182/blood-2014-06-582809"}], "href": "https://doi.org/10.1182/blood-2014-06-582809"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "25224413"}], "href": "https://pubmed.ncbi.nlm.nih.gov/25224413"}]}, {"type": "r", "ref": 13, "children": [{"type": "t", "text": "Yiping Wang, Mengtao Xiao, Xiufei Chen, et al. "}, {"type": "b", "children": [{"type": "t", "text": "WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Mol Cell (2015)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.molcel.2014.12.023"}], "href": "https://doi.org/10.1016/j.molcel.2014.12.023"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "25601757"}], "href": "https://pubmed.ncbi.nlm.nih.gov/25601757"}]}, {"type": "r", "ref": 14, "children": [{"type": "t", "text": "Qian Zhang, Kai Zhao, Qicong Shen, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Nature (2015)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/nature15252"}], "href": "https://doi.org/10.1038/nature15252"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "26287468"}], "href": "https://pubmed.ncbi.nlm.nih.gov/26287468"}]}, {"type": "r", "ref": 15, "children": [{"type": "t", "text": "Lulu Hu, Junyan Lu, Jingdong Cheng, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Structural insight into substrate preference for TET-mediated oxidation."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Nature (2015)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/nature15713"}], "href": "https://doi.org/10.1038/nature15713"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "26524525"}], "href": "https://pubmed.ncbi.nlm.nih.gov/26524525"}]}, {"type": "r", "ref": 16, "children": [{"type": "t", "text": "Ana Carolina da Silva Almeida, Francesco Abate, Hossein Khiabanian, et al. "}, {"type": "b", "children": [{"type": "t", "text": "The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Nat Genet (2015)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/ng.3442"}], "href": "https://doi.org/10.1038/ng.3442"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "26551667"}], "href": "https://pubmed.ncbi.nlm.nih.gov/26551667"}]}, {"type": "r", "ref": 17, "children": [{"type": "t", "text": "Manuel Buscarlet, Sylvie Provost, Yassamin Feroz Zada, et al. "}, {"type": "b", "children": [{"type": "a", "children": [{"type": "t", "text": "i"}], "href": "i"}, {"type": "t", "text": "DNMT3A"}, {"type": "a", "children": [{"type": "t", "text": "/i"}], "href": "/i"}, {"type": "t", "text": " and "}, {"type": "a", "children": [{"type": "t", "text": "i"}], "href": "i"}, {"type": "t", "text": "TET2"}, {"type": "a", "children": [{"type": "t", "text": "/i"}], "href": "/i"}, {"type": "t", "text": " dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Blood (2017)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1182/blood-2017-04-777029"}], "href": "https://doi.org/10.1182/blood-2017-04-777029"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "28655780"}], "href": "https://pubmed.ncbi.nlm.nih.gov/28655780"}]}, {"type": "r", "ref": 18, "children": [{"type": "t", "text": "Lena Dorsheimer, Birgit Assmus, Tina Rasper, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Association of Mutations Contributing to Clonal Hematopoiesis With Prognosis in Chronic Ischemic Heart Failure."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "JAMA Cardiol (2019)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1001/jamacardio.2018.3965"}], "href": "https://doi.org/10.1001/jamacardio.2018.3965"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "30566180"}], "href": "https://pubmed.ncbi.nlm.nih.gov/30566180"}]}, {"type": "r", "ref": 19, "children": [{"type": "t", "text": "A Tefferi, A Pardanani, K-H Lim, et al. "}, {"type": "b", "children": [{"type": "t", "text": "TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Leukemia (2009)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/leu.2009.47"}], "href": "https://doi.org/10.1038/leu.2009.47"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "19262601"}], "href": "https://pubmed.ncbi.nlm.nih.gov/19262601"}]}, {"type": "r", "ref": 20, "children": [{"type": "t", "text": "Anna M Jankowska, Hadrian Szpurka, Ramon V Tiu, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Blood (2009)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1182/blood-2009-02-205690"}], "href": "https://doi.org/10.1182/blood-2009-02-205690"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "19372255"}], "href": "https://pubmed.ncbi.nlm.nih.gov/19372255"}]}, {"type": "r", "ref": 21, "children": [{"type": "t", "text": "François Delhommeau, Sabrina Dupont, Véronique Della Valle, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Mutation in TET2 in myeloid cancers."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "N Engl J Med (2009)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1056/NEJMoa0810069"}], "href": "https://doi.org/10.1056/NEJMoa0810069"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "19474426"}], "href": "https://pubmed.ncbi.nlm.nih.gov/19474426"}]}, {"type": "r", "ref": 22, "children": [{"type": "t", "text": "Rosalind A Eeles, Zsofia Kote-Jarai, Ali Amin Al Olama, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Identification of seven new prostate cancer susceptibility loci through a genome-wide association study."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Nat Genet (2009)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/ng.450"}], "href": "https://doi.org/10.1038/ng.450"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "19767753"}], "href": "https://pubmed.ncbi.nlm.nih.gov/19767753"}]}, {"type": "r", "ref": 23, "children": [{"type": "t", "text": "Olivier Kosmider, Véronique Gelsi-Boyer, Marion Ciudad, et al. "}, {"type": "b", "children": [{"type": "t", "text": "TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Haematologica (2009)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.3324/haematol.2009.011205"}], "href": "https://doi.org/10.3324/haematol.2009.011205"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "19797729"}], "href": "https://pubmed.ncbi.nlm.nih.gov/19797729"}]}, {"type": "r", "ref": 24, "children": [{"type": "t", "text": "Franz X Schaub, Renate Looser, Sai Li, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Blood (2010)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1182/blood-2009-09-245381"}], "href": "https://doi.org/10.1182/blood-2009-09-245381"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "20061559"}], "href": "https://pubmed.ncbi.nlm.nih.gov/20061559"}]}, {"type": "r", "ref": 25, "children": [{"type": "t", "text": "A Tefferi, T L Lasho, O Abdel-Wahab, et al. "}, {"type": "b", "children": [{"type": "t", "text": "IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Leukemia (2010)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/leu.2010.113"}], "href": "https://doi.org/10.1038/leu.2010.113"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "20508616"}], "href": "https://pubmed.ncbi.nlm.nih.gov/20508616"}]}, {"type": "r", "ref": 26, "children": [{"type": "t", "text": "Alexander E Smith, Azim M Mohamedali, Austin Kulasekararaj, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Blood (2010)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1182/blood-2010-03-274704"}], "href": "https://doi.org/10.1182/blood-2010-03-274704"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "20693430"}], "href": "https://pubmed.ncbi.nlm.nih.gov/20693430"}]}, {"type": "r", "ref": 27, "children": [{"type": "t", "text": "Véronique Gelsi-Boyer, Virginie Trouplin, Julien Roquain, et al. "}, {"type": "b", "children": [{"type": "t", "text": "ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Br J Haematol (2010)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1111/j.1365-2141.2010.08381.x"}], "href": "https://doi.org/10.1111/j.1365-2141.2010.08381.x"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "20880116"}], "href": "https://pubmed.ncbi.nlm.nih.gov/20880116"}]}, {"type": "r", "ref": 28, "children": [{"type": "t", "text": "R Itzykson, O Kosmider, T Cluzeau, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Leukemia (2011)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/leu.2011.71"}], "href": "https://doi.org/10.1038/leu.2011.71"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "21494260"}], "href": "https://pubmed.ncbi.nlm.nih.gov/21494260"}]}, {"type": "r", "ref": 29, "children": [{"type": "t", "text": "S Weissmann, T Alpermann, V Grossmann, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Landscape of TET2 mutations in acute myeloid leukemia."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Leukemia (2012)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/leu.2011.326"}], "href": "https://doi.org/10.1038/leu.2011.326"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "22116554"}], "href": "https://pubmed.ncbi.nlm.nih.gov/22116554"}]}, {"type": "r", "ref": 30, "children": [{"type": "t", "text": "Lambert Busque, Jay P Patel, Maria E Figueroa, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Nat Genet (2012)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/ng.2413"}], "href": "https://doi.org/10.1038/ng.2413"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "23001125"}], "href": "https://pubmed.ncbi.nlm.nih.gov/23001125"}]}, {"type": "r", "ref": 31, "children": [{"type": "t", "text": "Lulu Hu, Ze Li, Jingdong Cheng, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Crystal structure of TET2-DNA complex: insight into TET-mediated 5mC oxidation."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Cell (2013)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.cell.2013.11.020"}], "href": "https://doi.org/10.1016/j.cell.2013.11.020"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "24315485"}], "href": "https://pubmed.ncbi.nlm.nih.gov/24315485"}]}, {"type": "r", "ref": 32, "children": [{"type": "t", "text": "Mamiko Sakata-Yanagimoto, Terukazu Enami, Kenichi Yoshida, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Somatic RHOA mutation in angioimmunoblastic T cell lymphoma."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Nat Genet (2014)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/ng.2872"}], "href": "https://doi.org/10.1038/ng.2872"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "24413737"}], "href": "https://pubmed.ncbi.nlm.nih.gov/24413737"}]}]}]}